Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Evaluation of HepaGam B™ in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients

Study:

Evaluation of HepaGam B™ in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients

Rationale:

n/a

Purpose:

The purpose of the study is to assess the pharmacokinetics, safety and efficacy of HepaGam B in combination with antiviral therapy for the prevention of hepatitis B virus (HBV) recurrence following HBV-related orthotopic liver transplant.

Study Status: Recruiting

Recruiting:
n/a

Condition Intervention Phase
Hepatitis B
Liver Transplantation
Biological: HepaGam B Phase 4

Verified by Cangene Corporation September, 2008

Sponsored by: Cangene Corporation
Information provided by: Cangene Corporation
ClinicalTrials.gov identifier: NCT00722332

Study Type: Interventional

Study Design: Prevention, Open Label, Single Group Assignment

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

n/a

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site